-
Look ahead five to 10 years, and you may see a male contraceptive on the market, as well as a microbicide for women that offers contraception as well as female-controlled protection against HIV and other sexually transmitted diseases (STDs), say reproductive health experts.
-
-
When the first combined oral contraceptive entered the marketplace in 1960, women began taking hormonally active pills for 21 days, followed by seven days of placebo pills, or no pills at all. This 21/7 regimen resulted in regular withdrawal bleeding every month. Such regular monthly cycles are a modern phenomenon.
-
Research has been a cornerstone of contraceptive technology; the following noninclusive list includes 25 articles of note from the past 25 years. Several selections are offered by Deborah Kowal, MA, adjunct assistant professor in the Rollins School of Public Health at Emory University in Atlanta, co-author of Contraceptive Technology, and the first editor for Contraceptive Technology Update.
-
You suspect that your 17-year-old patient may have a chlamydia infection. Thanks to a nucleic acid amplification screen on a urine specimen, you are able to detect the sexually transmitted disease (STD) and report the results the next day.
-
American women are one step closer to having a contraceptive implant option with the recent Food and Drug Administration (FDA) issuance of approvable status for Implanon, the single-rod contraceptive implant from Organon (West Orange, NJ).
-
-
-
Results from the estrogen-progestin arm of the Womens Health Initiative confirm (after central adjudication of the diagnoses) an increase in venous thrombosis associated with a standard dose of postmenopausal hormone therapy.
-
Nearly 70% of patients achieving a CR after primary therapy eventually recurred. Most recurrences occurred more than 6 months from completion of primary chemotherapy, and the use of second line agents at the time of recurrence was effective.
